(19)
(11) EP 4 771 049 A1

(12)

(43) Date of publication:
08.07.2026 Bulletin 2026/28

(21) Application number: 24772814.0

(22) Date of filing: 28.08.2024
(51) International Patent Classification (IPC): 
C07K 16/28(2006.01)
C07K 14/715(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 16/2866; C07K 14/7158; C07K 2317/76; A61K 35/28; C12N 2310/20; C12N 15/1138
(86) International application number:
PCT/US2024/044111
(87) International publication number:
WO 2025/049524 (06.03.2025 Gazette 2025/10)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 28.08.2023 US 202363579165 P
18.12.2023 US 202363611395 P

(71) Applicant: Regeneron Pharmaceuticals, Inc.
Tarrytown, NY 10591 (US)

(72) Inventors:
  • MOORE, Michael John
    Tarrytown, New York 10591 (US)
  • HACKETT, Caroline Gray
    Tarrytown, New York 10591 (US)
  • MURPHY, Andrew J.
    Tarrytown, New York 10591 (US)
  • PANEA, Casandra Maria
    Tarrytown, New York 10591 (US)
  • EDELMANN, Kurt Hans-Erwin Otto
    Tarrytown, New York 10591 (US)
  • FRANKLIN, Matthew C.
    Tarrytown, New York 10591 (US)
  • HO, Jo-Hao
    Tarrytown, New York 10591 (US)
  • KIM, Jee H.
    Tarrytown, New York 10591 (US)
  • MCGOLDRICK, Luke Lawrence Reedy
    Tarrytown, New York 10591 (US)
  • SAOTOME, Kei
    Tarrytown, New York 10591 (US)

(74) Representative: Mewburn Ellis LLP 
Aurora Building Counterslip
Bristol BS1 6BX
Bristol BS1 6BX (GB)

   


(54) CXCR4 ANTIBODY-RESISTANT MODIFIED RECEPTORS